The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
 
Yan Zhang
No Relationships to Disclose
 
Lin Zhou
No Relationships to Disclose
 
Youling Gong
No Relationships to Disclose
 
Meijuan Huang
No Relationships to Disclose
 
Min Tang
No Relationships to Disclose
 
Yongmei Liu
No Relationships to Disclose
 
Min Yu
No Relationships to Disclose
 
Weigang Xiu
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Xinyu Liu
Employment - GenEros BioPharma
 
Xin-Yuan Fu
Employment - GenEros BioPharma
Leadership - GenEros BioPharma
 
You Lu
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech